Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
APRILIAH
2023-506975-83-00Phase 3Completed
- Sponsor
- Aprogen
- Start
- Mar 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 15
01
Overview
Phase 3 trial of inetetamab in breast cancer, sponsored by Aprogen. Started Mar 2024; status: completed.
02
Drugs
inetetamab
03
Conditions
breast cancer
Beyond the preview
Go deeper on 2023-506975-83-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-506975-83-00.